APA (7th ed.) Citation

M, S., B, R., E, D., SE, G., A, F. C., X, T., . . . N, A. (2024). Challenges in the Assessment of a Disease Model in the NICE Single Technology Appraisal of Tirzepatide for Treating Type 2 Diabetes: An External Assessment Group Perspective. PharmacoEconomics, 42(8), 829. https://doi.org/10.1007/s40273-024-01394-8

Chicago Style (17th ed.) Citation

M, Scholte, et al. "Challenges in the Assessment of a Disease Model in the NICE Single Technology Appraisal of Tirzepatide for Treating Type 2 Diabetes: An External Assessment Group Perspective." PharmacoEconomics 42, no. 8 (2024): 829. https://doi.org/10.1007/s40273-024-01394-8.

MLA (9th ed.) Citation

M, Scholte, et al. "Challenges in the Assessment of a Disease Model in the NICE Single Technology Appraisal of Tirzepatide for Treating Type 2 Diabetes: An External Assessment Group Perspective." PharmacoEconomics, vol. 42, no. 8, 2024, p. 829, https://doi.org/10.1007/s40273-024-01394-8.